Blueprint Medicines (NASDAQ:BPMC) Trading Down 5.2%

Shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) were down 5.2% during trading on Friday . The company traded as low as $47.41 and last traded at $47.41. Approximately 13,072 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 460,386 shares. The stock had previously closed at $50.00.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company raised shares of Blueprint Medicines from an “underweight” rating to an “equal weight” rating and set a $41.00 price objective on the stock in a report on Monday, January 2nd. SVB Leerink dropped their price objective on shares of Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating on the stock in a report on Wednesday, November 2nd. Jefferies Financial Group dropped their price objective on shares of Blueprint Medicines from $84.00 to $80.00 in a report on Wednesday, November 2nd. JMP Securities dropped their price objective on shares of Blueprint Medicines from $152.00 to $114.00 and set a “market outperform” rating on the stock in a report on Friday, November 4th. Finally, Wedbush dropped their price objective on shares of Blueprint Medicines from $120.00 to $106.00 and set an “outperform” rating on the stock in a report on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.00.

Blueprint Medicines Stock Performance

The stock has a market cap of $2.86 billion, a P/E ratio of -3.95 and a beta of 0.64. The company has a debt-to-equity ratio of 0.19, a current ratio of 6.99 and a quick ratio of 6.79. The firm’s 50-day moving average price is $45.08 and its 200-day moving average price is $55.33.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last released its quarterly earnings data on Tuesday, November 1st. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.51) by $0.28. The firm had revenue of $65.98 million for the quarter, compared to analysts’ expectations of $43.49 million. Blueprint Medicines had a negative net margin of 263.54% and a negative return on equity of 56.45%. Sell-side analysts expect that Blueprint Medicines Co. will post -9.38 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction on Monday, December 5th. The shares were sold at an average price of $50.09, for a total value of $1,001,800.00. Following the sale, the director now owns 183,243 shares in the company, valued at $9,178,641.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction on Monday, December 5th. The shares were sold at an average price of $50.09, for a total value of $1,001,800.00. Following the sale, the director now owns 183,243 shares in the company, valued at $9,178,641.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kate Haviland purchased 1,100 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, November 3rd. The stock was acquired at an average price of $43.98 per share, for a total transaction of $48,378.00. Following the transaction, the chief executive officer now directly owns 92,281 shares of the company’s stock, valued at approximately $4,058,518.38. The disclosure for this purchase can be found here. Company insiders own 3.42% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in Blueprint Medicines by 50.7% during the second quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 230 shares during the last quarter. Captrust Financial Advisors increased its position in Blueprint Medicines by 2.5% during the first quarter. Captrust Financial Advisors now owns 16,206 shares of the biotechnology company’s stock valued at $1,035,000 after acquiring an additional 401 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in Blueprint Medicines by 19.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,719 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 434 shares during the last quarter. Bellevue Group AG increased its position in Blueprint Medicines by 2.0% during the first quarter. Bellevue Group AG now owns 26,000 shares of the biotechnology company’s stock valued at $1,661,000 after acquiring an additional 500 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Blueprint Medicines by 3.8% during the third quarter. Envestnet Asset Management Inc. now owns 14,393 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 521 shares during the last quarter.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Featured Stories

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.